Biogen, Eisai’s lecanemab will get Alzheimer’s nod, however how profitable it is going to be is unsure

Biogen, Eisai’s lecanemab will get Alzheimer’s nod, however how profitable it is going to be is unsure

Old man patient

agrobacter/iStock through Getty Photos

The US FDA on Friday granted accelerated approval to Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALY) Leqembi (lecanemab), simply the second biologic drugs ever accepted for Alzheimer’s illness.

The remedy is anticipated to turn into out there across the